Reverse merger, offering to fund Ignyta's personalized meds
This article was originally published in Scrip
Executive Summary
San Diego-based Ignyta's private offering of $47m in common stock is another step in the company's gradual shift from a diagnostics firm to a personalized medicine developer, which officially began in May when it acquired Actagene Oncology.